1 ng/ml. The LLOQ, 0.1 ng/ml, was sensitive enough for detecting terminal phase concentrations check details of the drug. Inter-batch precision of the method ranged from 2.2 to 5.55 %, while Inter-batch accuracy ranged from 95.5 to 100.0%. Intra-batch
precision ranged from 1.8 to 5.6%, while Intra-batch accuracy ranged from 92.0 to 99.4% at concentrations of 0.3 ng/ml, 20.0 and 40.0 ng/ml. The developed method was applied to a bioequivalenc study of CYP acetate in a group of 44 female volunteers at a single oral dose of a 2 mg tablet, in a combination of ethinylestradiol/CYP acetate (0.25/2 mg). The plasma concentration of CYP acetate did not differ significantly after administration of both formulations (test formulation and the reference one). The geometric mean and respective 90 % Cl of CYP acetate test/reference percent ratios were 90.66 % (84.39-97.40%) for C(max) and 96.20% (90.45-102.33%) for AUC(0-t).”
“This review summarizes developments in labels for rapid immunotests. Their application in bio-imaging in cellular and molecular biology, biosensing and biotechnology is becoming interesting as a tool for rapid tests Compound C manufacturer and point-of-care techniques. For each label, we discuss the possibility of simultaneous detection of multiple analytes
and reader application. (C) 2013 Elsevier Ltd. All rights reserved.”
“This article gives a brief overview of the most relevant examples of solid-phase microextraction (SPME) fibers with metal wires as substrates, mainly concerning different preparation strategies including physical coating, chemical bonding and some other preparation techniques, which involved various sorbent materials (e.g., polymers, nanomaterials, mesoporous materials, metal-organic frameworks, and ionic liquids). (C) 2013 Elsevier Ltd. All selleck screening library rights reserved.”
“Background and objective: Many drug products containing the same amount of active drug are made and marketed by more than one pharmaceutics manufacturer. Since the quality of final drug product is affected by the source of ingredients, type and amount
of excipients and manufacturing process, bioequivalence studies are used to determine the bioavailabillity and characterize the pharmacokinetics of the new formulation relative to a reference formulation. In the present study the bioavailability of a new capsule formulation of fexofenadine (CAS 153439-40-8) was compared to a reference formulation in 12 healthy male volunteers.
Methods. The blood samples were collected at different time points. After centrifugation and decanting the plasma, the drug was extracted using a mixture of diethyl ether/isopropyl alcohol (5:95 %v/v). Then the samples were dried at 45 degrees C under nitrogen and finally, after dissolving the dried sample in mobile phase, the plasma drug concentrations were determined using HPLC.